Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140712
Status:
COMPLETED
Last Update Posted:
2017-09-11
First Post:
2005-08-31
Brief Title:
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Study to Determine the Tolerability and Pharmacokinetics for Ropinirole in Paediatric Adolescent Patients With RLS Type 2
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome RLS in order to determine the starting dose for the ropinirole titration regimen for this age group Patients will receive two single doses unless poor tolerability is observed following the first dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None